Eudaldo Aponte, APRN
Psychiatric/Mental Health · Hialeah, FLNPI 1720450166
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,580 of the $214,400 with a category attached, or 81.4%. 16 manufacturers reported payments, led by AbbVie at 38.7% of the total. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 655 payments — averaging $327.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Teva Pharmaceuticals USA, Inc.$74K
- Alkermes, Inc.$30K
- Johnson & Johnson$14K
- Otsuka America Pharmaceutical, Inc.$7K
- Neurocrine Biosciences, Inc.$5K
- plus $2K from 10 others
What the payments were for
- Consulting fees$5,7553%
- Speaking & faculty fees$174,58081%
- Travel & lodging$19,1829%
- Food & beverage$14,8047%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 180 | $82,938 |
| Teva Pharmaceuticals USA, Inc. | 166 | $73,637 |
| Alkermes, Inc. | 78 | $29,695 |
| Johnson & Johnson | 46 | $14,052 |
| Otsuka America Pharmaceutical, Inc. | 50 | $6,972 |
| Neurocrine Biosciences, Inc. | 42 | $4,652 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $1,040 |
| Bausch Health US, LLC | 13 | $280 |
| Vanda Pharmaceuticals Inc. | 9 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $215 |
| Axsome Therapeutics, Inc. | 5 | $191 |
| Sunovion Pharmaceuticals Inc. | 15 | $164 |
| Supernus Pharmaceuticals, Inc. | 5 | $158 |
| Lundbeck LLC | 3 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$113,684
- VRAYLAR$80,692
- Austedo XR$38,964
- ARISTADA INITIO$28,421
- AUSTEDO$22,616
- INVEGA SUSTENNA$13,237
- INVEGA TRINZA$13,112
- UZEDY$9,256
- ABILIFY MAINTENA$6,147
- ABILIFY ASIMTUFII$5,034
- INGREZZA$3,658
- LYBALVI$1,020
- CAPLYTA$478
- QELBREE$126
- Auvelity$110
- REXULTI$108
How this compares
$214,400 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $86,442 |
| RexultiBrexpiprazole | 51 | $78,617 |
| VraylarCariprazine Hcl | 38 | $68,004 |
| AustedoDeutetrabenazine | 12 | $58,452 |
| TrintellixVortioxetine Hydrobromide | 77 | $46,016 |
| CaplytaLumateperone Tosylate | 16 | $26,413 |
| Lurasidone Hcl | 68 | $10,319 |
| Aripiprazole | 111 | $4,931 |
| Temazepam | 159 | $2,641 |
| Quetiapine Fumarate | 191 | $2,459 |
| Duloxetine Hcl | 113 | $2,235 |
| Olanzapine | 85 | $2,214 |
| Mirtazapine | 154 | $1,965 |
| Oxcarbazepine | 59 | $1,930 |
| Clonazepam | 328 | $1,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $4,652 | $86,44211 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $6,972 | $78,61751 claims |
| AbbVieVraylar | $82,938 | $68,00438 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $73,637 | $58,45212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $215 | $46,01677 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,040 | $26,41316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Hialeah
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
- Linda SkalskyGainesville$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.